@article {Setianingrum2021.04.25.21256062, author = {Findra Setianingrum and Anna Rozaliyani and Robiatul Adawiyah and Ridhawati Syam and Mulyati Tugiran and Cut Yulia I. Sari and Finny Nandipinto and Johannes Ramnath and Arief Riadi Arifin and Diah Handayani and Erlina Burhan and Martin C. Rumende and Retno Wahyuningsih and Riina Rautemaa-Richardson and David W. Denning}, title = {A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL)}, elocation-id = {2021.04.25.21256062}, year = {2021}, doi = {10.1101/2021.04.25.21256062}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives Chronic pulmonary aspergillosis (CPA) can complicate recovery from pulmonary tuberculosis (TB). CPA may also be misdiagnosed as bacteriologically-negative TB. This study aimed to determine the incidence of CPA in patients treated for TB in Indonesia; a country with a high incidence of TB.Methods In this prospective, longitudinal cohort study in patients treated for pulmonary TB, clinical, radiological and laboratory findings were analysed. Sputum was collected for fungal culture and TB PCR. Patients were assessed at baseline (0-8 weeks) and at the end (5-6 months) of TB therapy. CPA diagnosis was based on symptoms (\>3 months), characteristic radiological features and positive Aspergillus serology, and categorized as proven, probable and possible.Results Of the 216 patients recruited, 128 (59\%) were followed up until end of TB therapy. At baseline, 91 (42\%) had microbiological evidence for TB. Aspergillus-specific IgG was positive in 64 (30\%) patients and went from negative to positive in 16 (13\%) patients during TB therapy. The incidence of proven and probable CPA at baseline was 6\% (n=12) and 2\% (n=5) and end of TB therapy 8\% (n=10) and 5\% (n=7), respectively. Six patients (2 with confirmed TB) developed an aspergilloma. Diabetes mellitus was a significant risk factor for CPA (p=0.040). Persistent cough (n=5, 50\%; p=0.005) and fatigue (n=6, 60\%; p=0.001) were the most common symptoms in CPA.Conclusion CPA should be considered a relatively frequent differential diagnosis in patients with possible or proven TB in Indonesia. Lack of awareness and limited access to Aspergillus-specific IgG tests and CT imaging are obstacles in establishing a CPA diagnosis.What is the key question?Do what extent is chronic pulmonary aspergillosis (CPA) both a) mistaken for TB and b) co-exists with TB during the course of 6 months therapyWhat is the bottom line?Features consistent with CPA were present in 6\% of patients when starting TB therapy and 8\% at the end of therapy, with some resolving and some developing CPA de novo during TB therapy. At the end of B therapy symptoms, cavitations with Aspergillus-specific IgG detectable were the key features of CPA.Why read on?Co-existence of TB and CPA is present in a substantial minority of patients starting and ending TB therapy, and needs addressing in terms of diagnosis, dual therapy and follow up.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEpidemiological studyFunding StatementThe scholarship to support the studies of the first author was provided by Lembaga Pengelola Dana Pendidikan (20160222045506), Republik Indonesia. Prof D Denning is partly supported by the NIHR Manchester Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the University Research Ethics Committee, University of Manchester (approval number 16416) and from the ethics committee of the Faculty of Medicine, Universitas Indonesia (approval number 672/UN2.F1/ETIK/2016).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are archived on University of Manchester servers are are available on request}, URL = {https://www.medrxiv.org/content/early/2021/04/27/2021.04.25.21256062}, eprint = {https://www.medrxiv.org/content/early/2021/04/27/2021.04.25.21256062.full.pdf}, journal = {medRxiv} }